j&j's q1 earnings miss was because of covid-19 vaccine: cfo joseph wolk
Published 2 years ago • 9.3K plays • Length 3:53Download video MP4
Download video MP3
Similar videos
-
4:16
j&j cfo on q1 earnings beat, covid vaccine pause in u.s.
-
5:11
johnson & johnson cfo joseph wolk on q4 earnings beat
-
3:41
johnson & johnson cfo breaks down mixed earnings report, full-year guidance
-
3:50
j&j cfo joseph wolk on q1 earnings
-
6:12
watch cnbc's full interview with johnson & johnson cfo joseph wolk
-
4:43
johnson & johnson ceo alex gorsky on what's in the pipeline, growth drivers and talc lawsuit
-
5:02
j&j ceo breaks down the plan to split into two public companies
-
7:08
j&j reports positive phase 1/2 covid-19 vaccine trial results
-
4:53
johnson & johnson cfo on q2 earnings, raising guidance, covid-19 and more
-
5:32
johnson & johnson cfo on q3 earnings, covid vaccine booster
-
2:37
johnson & johnson cfo on third-quarter earnings results
-
6:07
j&j cfo joseph wolk on q2 earnings beat: we're in a very strong position for second half of 2023
-
2:50
j&j beats on eps, misses on sales in q3 earnings report
-
7:59
j&j cfo on q1 earnings, forecast and product pipeline
-
3:48
great scientific innovation continues to produce great financial results for our company: j&j cfo
-
9:02
jnj pharmaceutical business will be on par with january, but medical device unit to see impact: cfo
-
1:30
u.s. government to pay $1 billion for 100 million doses of johnson & johnson covid-19 vaccine
-
1:27
johnson & johnson reports q3 earnings beat, raises full-year guidance
-
11:03
johnson & johnson cfo talks earnings, vaccines
-
5:20
j&j says its one-shot covid-19 vaccine is 72% effective in the u.s.
-
9:42
johnson & johnson cfo on q2 earnings, litigation, product pipeline
-
2:02
j&j covid-19 vaccine shows promising results in primates